Artemisinin

• CAT Number: A000216
• CAS Number: 63968-64-9
• Molecular Formula: C15H22O5
• Molecular Weight: 282.30
• Purity: ≥95%
• Synonyms: Arteannuin; 63968-64-9; Artemisinine; Coartem, 63968-64-9; Artemisnini
• Target: PI3K/Akt/mTOR
• Storage: -20°C
• IUPAC Name: (1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
• InChI: InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
• InChIKey: BLUAFEHZUWYNDE-NNWCWBAJSA-N
• SMILES: C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)C

Artemisinin（Cat No.:A000216）is a natural compound derived from the sweet wormwood plant (Artemisia annua), widely known for its potent antimalarial properties. It contains a unique peroxide bridge that plays a key role in its mechanism of action, disrupting the malaria parasite’s cellular processes. Artemisinin is effective against multidrug-resistant malaria strains and is often used in combination therapies. Its application extends beyond malaria, with research exploring its potential for treating cancer, bacterial infections, and other diseases. Due to its high potency, Artemisinin is essential in global malaria treatment strategies.

Reference

1: Apinjoh TO, Mugri RN, Miotto O, Chi HF, Tata RB, Anchang-Kimbi JK, Fon EM,
Tangoh DA, Nyingchu RV, Jacob C, Amato R, Djimde A, Kwiatkowski D, Achidi EA,
Amambua-Ngwa A. Molecular markers for artemisinin and partner drug resistance in
natural Plasmodium falciparum populations following increased insecticide treated
net coverage along the slope of mount Cameroon: cross-sectional study. Infect Dis
Poverty. 2017 Nov 6;6(1):136. doi: 10.1186/s40249-017-0350-y. PubMed PMID:
29110722.

2: Yuan DS, Chen YP, Tan LL, Huang SQ, Li CQ, Wang Q, Zeng QP. Artemisinin: A
Panacea Eligible for Unrestrictive Use? Front Pharmacol. 2017 Oct 17;8:737. doi:
10.3389/fphar.2017.00737. eCollection 2017. PubMed PMID: 29089893; PubMed Central
PMCID: PMC5651041.

3: Moore BR, Davis WA, Clarke PM, Robinson LJ, Laman M, Davis TME.
Cost-effectiveness of artemisinin-naphthoquine versus artemether-lumefantrine for
the treatment of uncomplicated malaria in Papua New Guinean children. Malar J.
2017 Oct 30;16(1):438. doi: 10.1186/s12936-017-2081-8. PubMed PMID: 29084540;
PubMed Central PMCID: PMC5663042.

4: Kaur H, Allan EL, Mamadu I, Hall Z, Green MD, Swamidos I, Dwivedi P, Culzoni
MJ, Fernandez FM, Garcia G, Hergott D, Monti F. Prevalence of substandard and
falsified artemisinin-based combination antimalarial medicines on Bioko Island,
Equatorial Guinea. BMJ Glob Health. 2017 Oct 15;2(4):e000409. doi:
10.1136/bmjgh-2017-000409. eCollection 2017. PubMed PMID: 29082025; PubMed
Central PMCID: PMC5652615.

5: Schallig HD, Tinto H, Sawa P, Kaur H, Duparc S, Ishengoma DS, Magnussen P,
Alifrangis M, Sutherland CJ. Randomised controlled trial of two sequential
artemisinin-based combination therapy regimens to treat uncomplicated falciparum
malaria in African children: a protocol to investigate safety, efficacy and
adherence. BMJ Glob Health. 2017 Aug 30;2(3):e000371. doi:
10.1136/bmjgh-2017-000371. eCollection 2017. PubMed PMID: 29082016; PubMed
Central PMCID: PMC5656137.

6: Kheang ST, Sovannaroth S, Ek S, Chy S, Chhun P, Mao S, Nguon S, Lek DS, Menard
D, Kak N. Correction to: Prevalence of K13 mutation and Day-3 positive
parasitaemia in artemisinin-resistant malaria endemic area of Cambodia: a
cross-sectional study. Malar J. 2017 Oct 27;16(1):435. doi:
10.1186/s12936-017-2073-8. PubMed PMID: 29078767; PubMed Central PMCID:
PMC5660448.

7: Landier J, Kajeechiwa L, Thwin MM, Parker DM, Chaumeau V, Wiladphaingern J,
Imwong M, Miotto O, Patumrat K, Duanguppama J, Cerqueira D, Malleret B, Rénia L,
Nosten S, von Seidlein L, Ling C, Proux S, Corbel V, Simpson JA, Dondorp AM,
White NJ, Nosten FH. Safety and effectiveness of mass drug administration to
accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial
in four villages of Eastern Myanmar. Wellcome Open Res. 2017 Sep 6;2:81. doi:
10.12688/wellcomeopenres.12240.1. eCollection 2017. PubMed PMID: 29062913; PubMed
Central PMCID: PMC5635445.

8: Kadioglu O, Chan A, Cong Ling Qiu A, Wong VKW, Colligs V, Wecklein S,
Freund-Henni Rached H, Efferth T, Hsiao WW. Artemisinin Derivatives Target
Topoisomerase 1 and Cause DNA Damage in Silico and in Vitro. Front Pharmacol.
2017 Oct 9;8:711. doi: 10.3389/fphar.2017.00711. eCollection 2017. PubMed PMID:
29062278; PubMed Central PMCID: PMC5640709.

9: Slezakova S, Ruda-Kucerova J. Anticancer Activity of Artemisinin and its
Derivatives. Anticancer Res. 2017 Nov;37(11):5995-6003. Review. PubMed PMID:
29061778.

10: Letchmanan K, Shen SC, Ng WK, Tan RBH. Application of transglycosylated
stevia and hesperidin as drug carriers to enhance biopharmaceutical properties of
poorly-soluble artemisinin. Colloids Surf B Biointerfaces. 2017 Oct 7;161:83-93.
doi: 10.1016/j.colsurfb.2017.10.020. [Epub ahead of print] PubMed PMID: 29054047.